Greenovation: Greenovation Receives BfArM Approval to Start Phase I Clinical Trial for MossaGal the WorldÂs First MossProduced Drug Candidate

Greenovation Biotech GmbH announced today that it has received approval to begin a phase I clinical trial in Europe for its first drug candidate mossaGal agalsidase from Germany's regulatory authority the Federal Institute for Drugs and Medical Devices BfA...